TITLE OF STUDY |
PHASE
|
INDICATION |
STATUS |
For definitions, visit Glossary |
| Efficacy and safety of inhaled human insulin (Exubera) compared with subcutaneous human insulin in the therapy of adult subjects with Type 1 or Type II Diabetes Mellitus and chronic obstructive pulmonary disease: A one year , multicenter, randomized, outpatient, open-label, parallel group comparative trial |
II |
COPD/DM |
On Hold |
A prospective, multinational, multicenter, double-blind, randomized, active-controlled trial to compare the effects of Lotrel (amlodipine / benazepril) to benazepril and hydrochlorothiazide combined on the reduction of cardiovascular morbidity and mortality in patients with high risk hypertension |
III |
Hypertension |
Ongoing Closed to Enrollment
|
| A Phase IIIB, 12-Month, Double-blind, Double-dummy, Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 µg x 2 Actuations Twice-daily and 80/4.5 µg x 2 Actuations Twice-daily Compared to Formoterol TBH 4.5 µg x 2 Inhalations Twice-daily in COPD Subjects |
III |
COPD |
Open Enrolling |
A multinational, randomized, double-blind, placebo-controlled, forced titration, 2 x 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT) |
III |
Type II Diabetes Mellitus |
Ongoing Closed to Enrollment
|
A multicenter, randomized, double blind, parallel design trial to evaluate the blood pressure lowering efficacy comparing moderate versus aggressive treatment regimen of Exforge in patients uncontrolled on ARB monotherapy |
III |
Hypertension |
Open Enrolling |
A SAFETY AND EFFICACY TRIAL EVALUATING THE USE OF APIXABAN FOR THE EXTENDED TREATMENT OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM |
III |
Deep Vein Thrombosis |
Open Enrolling |
An Epidemiologic Study Of Xolair® (Omalizumab): Evaluating Clinical Effectiveness And Long-Term Safety In Patients With Moderate To Severe Asthma (EXCELS) |
Observational Survey |
Asthma |
Ongoing Closed to Enrollment
|
Effect of Roflumilast on Exacerbation Rate in Patients with COPD. A 52-week, double-blind study with 500 mcg Roflumilast once daily versus placebo |
III |
COPD |
Ongoing, closed to enrollment
|
Closed Studies
Visit Closed Studies
|
